Literature DB >> 16789629

Different mutations within or upstream of the GNAS locus cause distinct forms of pseudohypoparathyroidism.

Harald Jüppner1, Murat Bastepe.   

Abstract

The term pseudohypoparathyroidism (PHP) refers to different disorders that are caused by mutations within GNAS or upstream of this complex genetic locus. GNAS gives rise to several different transcripts, including Gs alpha (alpha-subunit of the heterotrimeric stimulatory G protein), XL alpha s (extra-large variant of Gs alpha), and several additional sense and antisense transcripts. The complexity of the GNAS locus is furthermore reflected by a parent-specific methylation pattern of most of its different promoters. PHP can be divided into two major groups, PHP type Ia (PHP-Ia) and PHP type Ib (PHP-Ib). PHP-Ia is caused by heterozygous mutations affecting one of the 13 GNAS exons encoding Gs alpha. In contrast, PHP-Ib is caused by heterozygous deletions within STX16, the gene encoding syntaxin 16, which is located more than 220 kb upstream of GNAS, or by deletions within GNAS involving exon NESP55 and two of the antisense exons. In either form of PHP, hormonal resistance develops only after maternal inheritance of the mutation, while paternal inheritance of the same molecular defect is not associated with endocrine abnormalities. In most familial cases of PHP-Ib, there is a loss of exon A/B methylation combined with active A/B transcription from both parental alleles, which leads to suppression of Gs alpha transcription in the proximal renal tubules and, therefore, PTH resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16789629     DOI: 10.1515/jpem.2006.19.s2.641

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  8 in total

1.  Recessive versus imprinted disorder: consanguinity can impede establishing the diagnosis of autosomal dominant pseudohypoparathyroidism type Ib.

Authors:  Serap Turan; Leyla Akin; Teoman Akcay; Erdal Adal; Sevil Sarikaya; Murat Bastepe; Harald Jüppner
Journal:  Eur J Endocrinol       Date:  2010-06-10       Impact factor: 6.664

2.  Osteocytes control myeloid cell proliferation and differentiation through Gsα-dependent and -independent mechanisms.

Authors:  Ehab Azab; Kevin Brown Chandler; Yuhei Uda; Ningyuan Sun; Amira Hussein; Raghad Shuwaikan; Veronica Lu; Catherine E Costello; Mark E McComb; Paola Divieti Pajevic
Journal:  FASEB J       Date:  2020-06-18       Impact factor: 5.191

3.  Imprinting status of Galpha(s), NESP55, and XLalphas in cell cultures derived from human embryonic germ cells: GNAS imprinting in human embryonic germ cells.

Authors:  Janet L Crane; Michael J Shamblott; Joyce Axelman; Stephanie Hsu; Michael A Levine; Emily L Germain-Lee
Journal:  Clin Transl Sci       Date:  2009-10       Impact factor: 4.689

4.  Preimplantation genetic diagnosis for severe albright hereditary osteodystrophy.

Authors:  Steven A Lietman; James Goldfarb; Nina Desai; Michael A Levine
Journal:  J Clin Endocrinol Metab       Date:  2007-12-18       Impact factor: 5.958

5.  Pseudohypoparathyroidism as a rare cause of bilateral slipped capital femoral epiphysis.

Authors:  Karthikeyan R Somasundaram; Senthilkumar Sankararaman; Athar Siddiqui; Hamid Zadeh
Journal:  Indian J Orthop       Date:  2012-11       Impact factor: 1.251

6.  A naturally occurring isoform inhibits parathyroid hormone receptor trafficking and signaling.

Authors:  Verónica Alonso; Juan A Ardura; Bin Wang; W Bruce Sneddon; Peter A Friedman
Journal:  J Bone Miner Res       Date:  2011-01       Impact factor: 6.741

Review 7.  Phosphate and FGF-23.

Authors:  Harald Jüppner
Journal:  Kidney Int Suppl       Date:  2011-02-23       Impact factor: 10.545

8.  Identification of a novel mutation in a patient with pseudohypoparathyroidism type Ia.

Authors:  Ye Seung Lee; Hui Kwon Kim; Hye Rim Kim; Jong Yoon Lee; Joong Wan Choi; Eun Ju Bae; Phil Soo Oh; Won Il Park; Chang Seok Ki; Hong Jin Lee
Journal:  Korean J Pediatr       Date:  2014-05-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.